NeurAxis, Inc. (AMEX: NRXS) is a Healthcare company (Biotechnology) with a market capitalization of $65M. The Maz Rating grades it against the other companies in its sector.
NeurAxis, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.61, NeurAxis, Inc. trades at 10.1x sales and 16.7x book value. Over the last twelve months it generated about $6M of revenue and a net loss of $15M. It runs a gross margin of 86.2%, an operating margin of -186.2% and a net margin of -188.2%. It shows return on equity of -252.1%, return on invested capital of -306.0% and a free cash flow yield of -9.8%. On the balance sheet: a debt-to-equity ratio of 0.10 and a current ratio of 2.10. Over the past 52 weeks the share price ranged from $2.21 to $9.33, with a beta of 1.38.
NeurAxis, Inc. does not currently pay a dividend.
1 Wall Street analyst rating covers the stock: 1 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.